MIGENIX, SCHERING-PLOUGH SIGN AGREEMENT

MIGENIX Inc., a clinical-stage developer of drugs for infectious and degenerative diseases, has completed a Material Transfer and License Option Agreement ("Agreement") with Schering-Plough Corporation of Kenilworth, N.J., related to celgosivir (MX-3253), MIGENIX's first-in- class compound in Phase II clinical development for the treatment of chronic Hepatitis C Virus (HCV) infections. Under the terms of the Agreement, Schering-Plough will supply PEGETRON(TM) (peginterferon alfa-2b powder for solution plus ribavirin 200 mg capsules) as well as provide certain technical and laboratory support and other services for MIGENIX's upcoming MX-3253 Phase II combination study in chronic HCV patients.

BioSpace (http://www.biospace.com/news_story.cfm?StoryID=20600320&full=1)